Sitagliptin triazecine analog
CAS: 2088771-61-1
Rif. 3D-FS180825
1g | Fuori produzione | ||
1mg | Fuori produzione | ||
2mg | Fuori produzione | ||
5mg | Fuori produzione | ||
50mg | Fuori produzione | ||
100mg | Fuori produzione | ||
250mg | Fuori produzione | ||
500mg | Fuori produzione | ||
250µg | Fuori produzione | ||
500µg | Fuori produzione |
Informazioni sul prodotto
Sitagliptin is a pharmaceutical drug that belongs to the group of dipeptidyl peptidase-4 (DPP-4) inhibitors. It is used to lower blood glucose levels in people with type 2 diabetes by increasing insulin release from the pancreas and by reducing the rate of breakdown of glucose-lowering medication. Sitagliptin can be administered orally, as an extended-release tablet or as an injection. It binds to human monocytes and reduces their production of proinflammatory cytokines such as TNF-α and IL-6, which are involved in the pathogenesis of atherosclerosis, diabetes, and obesity. Sitagliptin also has antihyperglycemic effects in animals.